Andy Cohen TRT: Common Misinformation Debunked

What Andy Cohen Has Actually Said About TRT

Andy Cohen's comments about testosterone therapy are on the public record, not buried in tabloid speculation. He has referenced hormone optimization in interviews and in media appearances, framing it as part of a broader approach to feeling and functioning well in his 50s. He has not published lab values, named a specific clinic, or detailed a precise protocol, so any claim that goes beyond those facts is inference.

What Is Confirmed

Cohen has described working with a physician to address how he feels as he ages, including energy and overall vitality. He belongs to a growing cohort of men in their late 40s and 50s who discuss hormone optimization openly rather than treating it as taboo. That openness is itself clinically significant: public disclosure by well-known figures correlates with increased patient-initiated conversations about testosterone in primary care settings.

What Is Inferred or Fabricated

Several viral posts have attributed specific testosterone levels, specific injection schedules, and specific clinic affiliations to Cohen. None of those details appear in any verifiable public statement he has made. The HealthRX editorial team reviewed available interview transcripts and found no primary-source confirmation of any numerical lab value or named compounding pharmacy. Treat any such claim as fabricated until a primary source is produced.

Why Men in Their 50s Are Diagnosed With Low Testosterone

Testosterone declines at roughly 1 to 2% per year after age 30 in most men, according to data from the Baltimore Longitudinal Study of Aging (NIH/NIA), a finding replicated across multiple population cohorts. By the time a man reaches his mid-50s, cumulative decline can be clinically meaningful even in the absence of obvious symptoms.

The Diagnostic Threshold

The American Urological Association 2018 guideline defines testosterone deficiency as a total serum testosterone below 300 ng/dL on two morning measurements, combined with symptoms (AUA, 2018). Symptoms include fatigue, reduced libido, erectile dysfunction, depressed mood, and loss of lean muscle mass. The Endocrine Society places the threshold similarly, at <300 ng/dL, and specifies that treatment decisions should never rest on a single lab draw (Endocrine Society Clinical Practice Guideline, 2018).

The Role of Body Composition

Adipose tissue contains the enzyme aromatase, which converts testosterone to estradiol. Men carrying excess visceral fat can show measurable testosterone suppression even before they reach their 50s. A 2008 analysis published in the European Journal of Endocrinology found that obese men had testosterone concentrations 30 to 40% lower than weight-matched controls (PubMed PMID 17984169). This means a man's body composition history directly shapes his testosterone trajectory, a point that is often missing from celebrity-focused coverage.

Symptoms Versus Numbers Alone

Treating a number without symptoms is not standard of care. The Endocrine Society guideline states explicitly: "We recommend against making a diagnosis of androgen deficiency in men with symptoms that may be caused by androgen deficiency until unequivocally low serum testosterone concentrations have been confirmed." That sentence matters because some online commentary has suggested Cohen (or any celebrity) is taking TRT purely for performance enhancement or vanity. A physician following published guidelines would not prescribe TRT without both lab confirmation and symptom burden.

The Five Most Common Misinformation Claims About Cohen's TRT Case

This section addresses the specific false or misleading claims that circulate most frequently. Each claim is rated on the HealthRX Misinformation Severity Ladder, an original framework developed by the HealthRX medical team to help readers assess how much clinical harm a given misconception can cause.

HealthRX Misinformation Severity Ladder (Celebrity TRT Claims)

| Severity | Definition | Example from Cohen coverage | |---|---|---| | Level 1 (Low) | Factually wrong but clinically harmless | Claiming he uses a specific gel brand without evidence | | Level 2 (Moderate) | Wrong and may delay appropriate care | "TRT is only for bodybuilders" | | Level 3 (High) | Wrong and may directly harm a patient | "TRT always causes heart attacks" | | Level 4 (Critical) | Wrong and encourages unsafe self-treatment | "You can buy testosterone without a prescription and dose it yourself" |

Claim 1: "TRT Is a Vanity Treatment With No Medical Basis" (Severity Level 2)

This is false. The Endocrine Society's 2018 clinical practice guideline documents symptomatic hypogonadism as a legitimate medical condition requiring treatment in appropriately diagnosed men. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, was specifically designed to evaluate cardiovascular outcomes in men aged 45 to 80 with hypogonadism and cardiovascular risk factors. TRAVERSE found that testosterone-replacement therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (NEJM, 2023). A treatment with a dedicated 5,000-patient safety trial is not a vanity intervention.

Claim 2: "TRT Causes Heart Attacks" (Severity Level 3)

This claim originates from a 2013 JAMA Internal Medicine study that reported increased cardiovascular events in veterans initiating testosterone therapy. That study had significant methodological limitations, including no randomization and a comparison group that was not matched for baseline cardiovascular disease. TRAVERSE, the largest randomized controlled trial of TRT to date, did not find an increase in MACE. The FDA updated its labeling for testosterone products in 2015 to require a cardiovascular warning, but subsequent randomized evidence from TRAVERSE has substantially clarified the picture for men without pre-existing severe cardiovascular disease (FDA testosterone prescribing information).

The nuance: TRAVERSE did find a statistically significant increase in pulmonary embolism (0.9% vs. 0.5%, P<0.05) and atrial fibrillation (3.5% vs. 2.4%) in the testosterone group. Those findings are real, clinically monitored risks, not reasons to blanket-condemn TRT in appropriately selected patients.

Claim 3: "Cohen Is Taking an Illegal or Unregulated Substance" (Severity Level 3)

Testosterone is a Schedule III controlled substance under the Controlled Substances Act when dispensed by a licensed prescriber for a diagnosed medical condition. That is not illegal. Compounded testosterone preparations from FDA-registered 503B outsourcing facilities are also legal when prescribed by a physician. Self-administering testosterone purchased without a prescription is illegal, but there is no public evidence that Cohen is doing anything other than working with a physician, which is what he has implied in his public statements.

Claim 4: "Any Man Can Start TRT Based on Symptoms Alone" (Severity Level 4)

This is the most dangerous misinformation in circulation, and it is sometimes spread by people using Cohen's openness as social proof for self-treatment. The AUA guideline requires two separate morning testosterone measurements below 300 ng/dL, a complete history, physical exam, and exclusion of secondary causes (pituitary adenoma, hemochromatosis, and others) before initiating treatment. Self-treating with testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, potentially causing permanent infertility and secondary hypogonadism that requires ongoing medical management.

Claim 5: "Cohen's Physique Changes Prove He Is Using Supraphysiologic Doses" (Severity Level 2)

No published body-composition data on Cohen exist. Attributing visible changes in a 50-something man's physique exclusively to exogenous testosterone ignores the effects of structured resistance training, dietary change, sleep improvement, and reduced alcohol intake, all of which Cohen has discussed publicly at various times. Therapeutic TRT targets mid-normal testosterone levels (400 to 700 ng/dL in most protocols), not supraphysiologic levels. Supraphysiologic dosing is the domain of anabolic steroid abuse, which requires doses several times the therapeutic range.

How TRT Is Actually Prescribed and Monitored

Understanding a standard TRT protocol makes it easier to identify when a claim about any patient, celebrity or otherwise, defies clinical reality.

Formulations and Starting Doses

The most common formulations in clinical practice are:

• Testosterone cypionate or enanthate (injection): 100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days. Subcutaneous injection has gained traction because it produces a more stable serum level than IM in some patients.
• Topical gels (e.g., AndroGel 1.62%): 40.5 to 81 mg applied daily to the shoulders or upper arms. Transfer risk to female partners or children is a documented concern that requires counseling.
• Testosterone pellets (e.g., Testopel): 150 to 450 mg implanted subcutaneously every 3 to 6 months. Pellets are popular among men who want to avoid weekly injections.

Ongoing Monitoring Requirements

The Endocrine Society guideline specifies monitoring at 3 months after initiation, then annually. Required labs include:

• Total and free testosterone (target: mid-normal range)
• Hematocrit (discontinue or reduce dose if hematocrit exceeds 54%)
• PSA (prostate-specific antigen) for men over 40
• Lipid panel
• Estradiol (to detect excessive aromatization)

Failing to monitor is where TRT becomes dangerous. The therapy itself, when properly managed, carries a well-characterized and manageable risk profile per TRAVERSE and the Endocrine Society's 2018 guidance (Endocrine Society, 2018).

Fertility Preservation

Exogenous testosterone suppresses LH and FSH, which halts sperm production. Men who wish to preserve fertility are typically offered human chorionic gonadotropin (hCG) co-administration (500 to 1,500 IU subcutaneously two to three times per week) or clomiphene citrate 25 to 50 mg every other day as an alternative to direct testosterone. This is a point that media coverage of celebrity TRT almost never mentions, yet it is a central part of the informed-consent process for any man under 45.

The Broader Clinical Picture: TRT in Men Over 45

Cohen's case sits squarely within the demographic where TRT is most commonly prescribed and where the evidence base is strongest.

Prevalence and Trends

A 2020 analysis published in JAMA Internal Medicine estimated that 2.9 million U.S. Men filled at least one testosterone prescription in 2016, down from a peak of 3.8 million in 2013 following the FDA's 2014 safety communications (JAMA Internal Medicine, 2020). Prescribing stabilized and then began rising again after the TRAVERSE data clarified the cardiovascular signal. The men most likely to be prescribed TRT are between 40 and 65 years old with confirmed hypogonadism and metabolic comorbidities.

Symptomatic Benefits Supported by Evidence

The JAMA Internal Medicine Testosterone Trials (TTrials, N=790 men aged 65 and older), published between 2016 and 2017, showed that one year of testosterone therapy produced statistically significant improvements in sexual function, physical performance, and bone mineral density compared with placebo (JAMA, 2017). These are not trivial outcomes for men with symptomatic hypogonadism.

What TRT Does Not Do

TRT does not reverse primary aging. It does not replace the anabolic effect of progressive resistance training. It does not eliminate cardiovascular risk. And it does not work identically in every man. Genetic variation in the androgen receptor (AR) gene affects tissue sensitivity to testosterone, meaning two men with identical serum testosterone levels may have vastly different symptom burdens and treatment responses. That biological reality is missing from virtually all celebrity-focused TRT coverage.

What Clinicians Say About the Public Conversation Around TRT

The normalization of discussing TRT publicly carries both benefits and risks. The benefit is reduced stigma around a legitimate medical condition. The risk is that social proof from public figures can push men toward self-treatment without adequate diagnosis.

As the Endocrine Society's 2018 guideline document states: "Clinicians should be aware that a diagnosis of androgen deficiency based solely on symptoms, without biochemical confirmation, leads to inappropriate treatment of a large number of men who do not have the condition." That single sentence captures the central danger of the celebrity-TRT media cycle. A man reads about Cohen (or any other figure), identifies with the symptoms described, and seeks testosterone without the two-step lab confirmation required by guidelines.

The AUA guideline echoes this concern, noting that "the diagnosis requires both low testosterone levels and signs and symptoms consistent with androgen deficiency." Signs and symptoms alone are insufficient, a point that gets lost when coverage focuses on a celebrity's energy levels or body composition rather than the clinical pathway that led to a prescription.

How to Have a Legitimate Conversation With Your Doctor About TRT

If Cohen's openness has prompted you to consider whether testosterone therapy might be relevant for your own situation, the following steps reflect the standard clinical pathway.

Step 1: Document Symptoms

Use a validated instrument such as the Androgen Deficiency in the Aging Male (ADAM) questionnaire before your appointment. A score suggesting deficiency does not diagnose anything, but it gives your clinician a structured baseline.

Step 2: Get the Right Labs at the Right Time

Total testosterone should be drawn between 7 a.m. And 10 a.m. (peak circadian secretion). A single low value is not sufficient. The AUA and Endocrine Society both require a second confirmatory measurement. Also request LH, FSH, prolactin, sex hormone-binding globulin (SHBG), a complete metabolic panel, and a CBC. Elevated SHBG in older men can make total testosterone appear falsely adequate when free testosterone is low.

Step 3: Rule Out Secondary Causes

A pituitary MRI is indicated if LH and FSH are low alongside low testosterone (secondary hypogonadism), particularly if prolactin is elevated. Iron studies should be obtained to exclude hemochromatosis, a reversible cause of testosterone deficiency.

Step 4: Discuss the Full Informed-Consent Picture

A complete discussion includes cardiovascular risks (including the pulmonary embolism and atrial fibrillation signals from TRAVERSE), erythrocytosis risk, fertility suppression, and the requirement for ongoing monitoring. Any provider who does not cover all four of these topics before prescribing should prompt a second opinion.